Adaptimmune Therapeutics (ADAP)
NASDAQ: ADAP
· Real-Time Price · USD
0.28
-0.00 (-1.06%)
At close: Jun 09, 2025, 3:58 PM
Adaptimmune Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -47.58M | -74.24M | -17.62M | 69.52M | -48.48M | -47.92M | -45.6M | -21.39M | 1.04M | -29.25M | -41.42M | -44.52M | -50.27M | -38.86M | -42.4M | -39.07M | -37.76M |
Depreciation & Amortization | 2.29M | 2.81M | 2.82M | 2.74M | 2.83M | 2.87M | 2.89M | 2.23M | 1.84M | 1.44M | 1.49M | 1.55M | 1.59M | 2.23M | 1.45M | 1.44M | 1.44M |
Stock-Based Compensation | 669K | 2.84M | 3.05M | 994K | 3.1M | 3.08M | 3.18M | 3.84M | 1.68M | 3.95M | 3.66M | 5.04M | 5.59M | 4.83M | 5.02M | 5.45M | 5.33M |
Other Working Capital | n/a | 6.69M | -45.53M | -32.52M | 2.39M | 30.3M | -4.7M | -5.88M | -42.65M | 25.43M | -10.21M | -4.26M | -12.29M | 164.86M | -11.37M | 746K | -19.59M |
Other Non-Cash Items | n/a | 8.79M | 2.82M | 1.48M | 1.05M | -988K | -934K | -22.56M | 809K | 474K | -1.68M | 365K | 975K | -1.07M | 838K | 102K | 1.3M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.94M | 1.26M | -131K | 2.75M |
Change in Working Capital | n/a | 25.81M | -45.53M | -27.35M | 10.35M | 28.28M | -4.7M | -5.81M | -42.65M | 25.43M | -10.21M | -4.47M | -12.29M | 164.86M | -11.37M | 746K | -19.59M |
Operating Cash Flow | -66.59M | -34.2M | -54.45M | n/a | -31.93M | -14.68M | -45.16M | -43.76M | -37.28M | 2.04M | -48.16M | -41.25M | -54.4M | 133.93M | -45.2M | -31.46M | -46.54M |
Capital Expenditures | n/a | -1.17M | -435K | -754.55K | -357.8K | -828.02K | -289K | -1.24M | -2.52M | -3.43M | -10.24M | -8.96M | -7.11M | -4.04M | -1.67M | -1.78M | -1.28M |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | -24.45K | n/a | 26K | n/a | -24.37M | -39.04M | n/a | 49.31M | 26K | 38K | 10K | 133K |
Purchase of Investments | n/a | -34.46M | -65.7M | n/a | n/a | -2.9M | -5.8M | -67.12M | n/a | -5.92M | 178.49K | 14.19K | -42.2M | -58.4M | 595K | -20.36M | -61.6M |
Sales Maturities Of Investments | 58.44M | 44.06M | n/a | n/a | n/a | 71.94M | 63.12M | 25.26M | 50.86M | 30.3M | 39.09M | 53.07M | 44.54M | 33.95M | 35.93M | 69.82M | 84.65M |
Other Investing Acitivies | -17.29M | -972.54K | 118.58K | -321K | -358K | 211.32K | 462.56K | 45.77M | 50.69M | 24.37M | 38.86M | 53.07M | -49.31M | -26K | -38K | -10K | -133K |
Investing Cash Flow | 41.15M | 8.17M | -66.02M | -743K | -357.8K | 68.4M | 57.31M | 2.69M | 48.34M | 20.95M | 28.85M | 44.11M | -4.78M | -28.49M | 34.85M | 47.68M | 21.76M |
Debt Repayment | n/a | n/a | 25M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -25.44M | n/a | 1K | 24.5M | 74K | 73K | 161K | 14K | 8K | 8K | 6K | 1K | 35K | 52K | 129K | 44K | 534K |
Financial Cash Flow | -25.32M | 1K | 25M | 24.51M | 29.22M | 74K | 596K | 14K | 196K | 1.4M | 1.45M | 9.98M | 35K | 52K | 139K | 2.56M | 534K |
Net Cash Flow | -50.2M | -26.22M | -95.25M | 71.15M | -3.32M | 53.95M | 12.87M | -41.24M | 11.84M | 28.89M | -18.81M | 8.27M | -60.41M | 107.03M | -10.45M | 18.05M | -24.45M |
Free Cash Flow | -66.59M | -35.38M | -54.89M | 46.63M | -32.29M | -15.5M | -45.45M | -45M | -39.8M | -1.39M | -58.4M | -50.21M | -61.52M | 129.89M | -46.87M | -33.24M | -47.83M |